Sorin Group Receives CE Mark Approval For the Mitroflow Aortic Pericardial Heart Valve with Phospholipid Reduction Treatment
The Phospholipid Reduction Treatment (PRT) on the Mitroflow Aortic Pericardial Heart Valve is designed to mitigate calcification of the bioprosthetic valve
Saluggia, Italy, July 28, 2011 – Sorin Group, (Reuters Code: SORN.MI), a global medical company and a leader in the treatment of cardiovascular diseases, announced today that it received the CE Mark approval for the Mitroflow™ Aortic Pericardial Heart Valve with PRT.
The Phospholipid Reduction Treatment (PRT), a proprietary advanced tissue treatment, is intended to prevent the potential calcification of the Mitroflow bioprosthetic valve. Research has demonstrated that phospholipids play a key role in the calcification process of biosprotheses.
PRT has been shown to decrease phospholipid content in the pericardial tissue, which leads to a reduction of up to 99% of calcium uptake in the treated pericardial tissue.
The addition of PRT to the Mitroflow bioprosthesis will help mitigate potential calcification and possibly further improve the tissue valve’s clinically proven outstanding durability. With close to 30 years of clinical use and over 20 years of exceptional peer-reviewed clinical outcomes, the Mitroflow valve has demonstrated excellent hemodynamic performance and long-term durability due to its proven design.
This enhancement demonstrates Sorin Group’s unwavering commitment to innovation and improvement of its tissue heart valve portfolio.
“We are extremely pleased to receive the CE Mark approval for the Mitroflow valve with PRT”, said Davide Bianchi, Sorin Group President Heart Valve Business Unit. “We trust the proven excellent performance of our bioprosthesis and we are pleased to provide patients and cardiothoracic surgeons with Mitroflow with PRT which will potentially lead to further enhancing the valve’s proven long-term performance.”
About Sorin Group
Sorin Group (www.sorin.com) is a global, medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,700 employees worldwide, Sorin Group focuses on three major therapeutic areas: cardiopulmonary bypass (extracorporeal circulation and autotransfusion systems), cardiac rhythm management, and heart valve repair and replacement. Every year, over one million patients are treated with Sorin Group devices in more than 80 countries.
For more information, please visit www.sorin.com, or contact:
Director, Corporate Communications
Tel: +33 (0)1 46 01 33 78
Mobile: +33 (0)6 76 12 67 73
Tel: +39 02 69969716